Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03929718 · ClinicalTrials.gov registry record · Early Phase 1
Efficacy of Aldosterone Antagonist Therapy for Prevention of New Atrial Fibrillation
A Early Phase 1 study of Afib, sponsored by Piedmont Healthcare.
- Active
- Registry status
- Early Phase 1
- Development phase
- 50
- Enrollment target
- 1
- Study location
NCT03929718 is a Early Phase 1 study of Afib that is active but no longer recruiting, run by Piedmont Healthcare. The registered enrollment target is 50 participants. The trial reports 1 study location across 1 state.
The verdict
NCT03929718, a Early Phase 1 study of Afib, is active but no longer recruiting, sponsored by Piedmont Healthcare.
- ACTIVE NOT RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to accurately determine, using an implantable rhythm monitor, the long-term incidence of new atrial fibrillation after ablation of atrial flutter in those treated with spironolactone compared with standard medical therapy.
Conditions Studied
Interventions
- DRUG Spironolactone
- DRUG No Spironolactone
Study Locations (1)
Georgia
- Piedmont Heart Institute - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2019-04-24 |
| Est. Completion | 2027-09 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03929718
The ClinicalTrials.gov registry entry for NCT03929718 describes a study currently listed as active not recruiting, categorized as Early Phase 1. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Piedmont Healthcare, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Afib appearing as the primary indexed condition, and to 2 interventions - of which Spironolactone is the first listed.
NCT03929718 reports 1 study location spanning 1 distinct geographic area - top geographies include Georgia.
Frequently Asked Questions
What is clinical trial NCT03929718 about?
NCT03929718 is a clinical study titled "Efficacy of Aldosterone Antagonist Therapy for Prevention of New Atrial Fibrillation". The purpose of this study is to accurately determine, using an implantable rhythm monitor, the long-term incidence of new atrial fibrillation after ablation of atrial flutter in those treated with spironolactone compared with standard medical therapy.
What is the current status of trial NCT03929718?
This trial is currently active not recruiting. It is a Early Phase 1 study. The enrollment target is 50 participants. The study started on 2019-04-24. Estimated completion is 2027-09.
What conditions does trial NCT03929718 study?
This clinical trial studies the following conditions: Afib.
What interventions are being tested in trial NCT03929718?
The interventions under investigation include: Spironolactone (DRUG), No Spironolactone (DRUG).
Who is sponsoring clinical trial NCT03929718?
This trial is sponsored by Piedmont Healthcare, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03929718 being conducted?
This trial has 1 study location across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Afib
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.